Syndeio debuts with $90M+ to bring together synapse repair drugs

Kyle LaHucik

Biotech Correspondent

An Indianapolis-headquartered biotech reentered the neuroscience scene with more than $90 million in funding on Tuesday morning, rolling up assets from Gate Neurosciences and Boost …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Syndeio debuts with $90M+ to bring together synapse repair drugs

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: Trump administration halts more than $750M in funds for Moderna’s bird flu vaccine

The fate of Moderna’s next-gen Covid shot looms large after a flurry of policy changes

A new dawn for psychedelics? Compass could be the first to find out

Novo Nordisk ‘strongly’ urges against pharma tariffs as comments flood in

Weeks after TIGIT fail, iTeos decides to wind down

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Syn­deio de­buts with $90M+ to bring to­geth­er synapse re­pair drugs

Biotech Correspondent

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Syndeio debuts with $90M+ to bring together synapse repair drugs